GLP1R and metabolic dysfunction-associated steatohepatitis: The GIP/GLP-1 dual agonist, tirzepatide, reduced liver fat and improved biomarkers of MASH and fibrosis in patients with type 2 diabetes (T2D); a phase 2 trial in MASH is ongoing7,8.